摘要
[目的]观察红霉素逆转头颈部肿瘤(唇癌、鼻咽癌、甲状腺未分化癌)多药耐药的临床疗效。[方法]采用免疫组化SP法检测唇癌、鼻咽癌及甲状腺未分化癌的P 糖蛋白(P gp)表达 ,将P gp表达阳性者(唇癌19例 ,鼻咽癌30例及甲状腺未分化癌10例)各随机分两组。红霉素加化疗组(试验组)与单化疗组(对照组) ,各自比较两组疗效。[结果]唇癌 :试验组CR +PR(70%)高于对照组(22.2%) ,P<0.05;鼻咽癌 :试验组CR +PR(72.7 %)高于对照组(47.4 %) ,P<0.05;甲状腺未分化癌 :试验组CR +PR(3/5)高于对照组(2/5)。[结论]红霉素逆转头颈部肿瘤(唇癌、鼻咽癌及甲状腺未分化癌)多药耐药 ,疗效较佳 。
To observe the reversing effect on multidrug resistance(MDR)by erythromycin in tumors of the head and neck(carcinoma of the lip,nasopharyngeal carcinoma,thyroid anaplastic carcinoma).The expression of P glycoprotein(P gp)was determined by immunohistochemistry SP way in tumors of the head and neck.The P gp positives cases were randomly divided into two groups.They included carcinoma of the lip 19 cases,nasopharyngeal carcinoma 30 cases and thyroid anaplastic carcinoma 10 cases.(1)chemotherapy and erythromycin(test group),(2)chemotherapy alone(control group).CR and PR in the test group(70%) were higher than that in control group(22.2%)on the carcinoma of the lip,P<0.05;CR and PR in the test group(72.7%)were higher than that in control group(47.4%) on nasopharyngeal carcinoma,P<0.05;CR and PR in the test group(3/5)were higher than that in control group(2/5)on the thyroid anaplastic carcinoma.[Conclusion]Erythromycin is very effective for the reversal of MDR in the tumors of the head and neck.It is worth to be recommended for clinical use.
出处
《肿瘤学杂志》
CAS
2001年第5期267-269,共3页
Journal of Chinese Oncology
